Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Bliss Gvs Pharma Limited ( (IN:BLISSGVS) ) has issued an announcement.
Bliss GVS Pharma Limited’s board approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, together with an unmodified audit opinion, underscoring the integrity of its reported financial performance. The board also recommended a final dividend of 100%, equal to Rs 1 per equity share, signaling confidence in the company’s financial position and providing direct returns to shareholders.
The company reappointed BDO India Services Private Limited as internal auditor for FY 2026-27, reinforcing its internal control and compliance processes. The board additionally scheduled the 41st Annual General Meeting for July 15, 2026, to be held via video conferencing and other audio-visual means, reflecting continued use of virtual formats in line with Ministry of Corporate Affairs guidance and ensuring broad shareholder participation without physical presence.
More about Bliss Gvs Pharma Limited
Bliss GVS Pharma Limited operates in the pharmaceutical industry, focusing on the development and manufacture of pharmaceutical products and serving both domestic and international healthcare markets. The company is listed on Indian stock exchanges and adheres to regulatory and disclosure norms under SEBI’s listing obligations framework.
Average Trading Volume: 97,407
Technical Sentiment Signal: Buy
Current Market Cap: 28.49B INR
For detailed information about BLISSGVS stock, go to TipRanks’ Stock Analysis page.